MedTrace Logo

Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD)

NCT00518570 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2007-08-20

No results posted yet for this study

Summary

The purpose of this study is to investigate the clinical efficacy of Levetiracetam in the treatment of symptoms of premenstrual dysphoric disorder (PMDD) in an open label study.

Conditions

  • Premenstrual Dysphoric Disorder

Interventions

DRUG

Levetiracetam

Levetiracetam was started at 250 mg qhs at the end of the first week of the follicular phase. Dose was gradually increased up to 1500 mg bid as tolerated or clinically effective. The treatment phase lasted 4 months.

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • Berkshire Health Systems

    lead OTHER

Principal Investigators

  • Zerrin E Kayatekin, MD · Berkshire Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-11-30
Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00518570 on ClinicalTrials.gov